The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy.
Patients and methods:
Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed.
Results:
The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy.
Conclusions:
The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.
SaitohH.Distant metastasis of renal adenocarcinoma. Cancer. 1981;48(6):1487-1491.
2.
DeckerDADeckerVLHerskovicACummingsGD.Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol. 1984;2(3):169-173.
3.
WronskiMMaorMHDavisBJSawayaRLevinVA.External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997;37(4):753-759.
4.
CulineSBekraddaMKramarAReyAEscudierBDrozJP.Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83(12): 2548-2553.
5.
CannadySBCavanaughKALeeSY, et al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys. 2004;58(1):253-258.
6.
NiederCSpanneONord0yTDalhaugA.Treatment of brain metastases from renal cell cancer. Urol Oncol. 2011;29(4): 405-410.
7.
MedioniJCojocarasuOBelcaceresJLHalimiPOudardS.Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007;18(7):1282-1283.
8.
KoutrasAKKrikelisDAlexandrouNStarakisIKalofonosHP.Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007;27(6C):4255-4257.
9.
HelgasonHHMalloHADroogendijkH, et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol. 2008;26(1):152-154.
10.
ThibaultFBillemontBRixeO.Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neuroon-col. 2008;86(2):243-244.
11.
ValcamonicoFFerrariVAmorosoV, et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol. 2009;91(1):47-50.
12.
LimZDMahajanAWeinbergJTannirNM.Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol. 2013; 36(3):258-260.
13.
StadlerWMFiglinRAMcDermottDF, et al. ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-1280.
14.
GoreMEHariharanSPortaC, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011;117(3):501-509.
15.
GoreMESzczylikCPortaC, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113(1):12-19.
16.
BreedveldPPluimDCiprianiG, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005;65(7):2577-2582.
17.
HuSChenZFrankeR, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15(19): 6062-6069.
18.
MorikawaAPeereboomDMThorsheimHR, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncol. 2015;17(2):289-295.
19.
PercyDBRibotEJChenY, et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011;46(11): 718-725.
20.
LyleLTLockmanPRAdkinsCE, et al. Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clin Cancer Res. 2016;22(21):5287-5299.
21.
MassardCZonierekJGross-GoupilMFizaziKSzczylikCEscudierB.Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010;21(5):1027-1031.
22.
VermaJJonaschEAllenPK, et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metas-tases from renal cell carcinoma. Am J Clin Oncol. 2013;36(6): 620-624.
23.
ChevreauCRavaudAEscudierB, et al. French Group on Renal Cancer. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer. 2014;12(1):50-54.
24.
ShuchBLa RochelleJCKlatteT, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008;113(7):1641-1648.
25.
SperdutoPWChaoSTSneedPK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3): 655-661.
26.
VickersMMAl-HarbiHChoueiriTK, et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer. 2013;11(3):311-315.
27.
BastosDAMolinaAMHatzoglouV, et al. Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clin Genitourin Cancer. 2015;13(1):59-66.
28.
GoldbergSBGettingerSNMahajanA, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7): 976-983.
29.
YushakMLChiangVLKlugerHM.Clinical trials in melanoma patients with brain metastases. Pigment Cell Melanoma Res. 2015;28(6):741-743.
30.
KniselyJPYuJBFlaniganJSznolMKlugerHMChiangVL. Radiosurgery for melanoma brain metastases in the ipilim-umab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227-233.
31.
CohenJVKlugerHM.Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.
32.
PatelKRLawsonDHKudchadkarRR, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-oncol. 2015;17(10): 1312-1321.
33.
FreyBRubnerYKulzerL, et al. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2014;63(1):29-36.
34.
LeeYAuhSLWangY, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589-595.
35.
Twyman-Saint VictorCRechAJMaityA, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-377.
36.
PostowMACallahanMKBarkerCA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931.
